Galactorrhea probably related with switching from osmotic-release oral system methylphenidate (MPH) to modified-release MPH: An adolescent case
Clinical Psychopharmacology and Neuroscience, cilt.15, sa.3, ss.282-284, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 3
- Basım Tarihi: 2017
- Doi Numarası: 10.9758/cpn.2017.15.3.282
- Dergi Adı: Clinical Psychopharmacology and Neuroscience
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.282-284
- Anahtar Kelimeler: Galactorrhea, Methylphenidate, Selective serotonin reuptake inhibitors, Adolescent
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Galactorrhea, as an adverse effect of psychotropic medications, usually develops due to high dose of antipsychotics. Selective serotonin reuptake inhibitors (SSRIs) have also been reported to be related to galactorrhea. To the best of our knowledge, no previous study reported galactorrhea with methylphenidate (MPH) use. Hereby, we report a case of an adolescent girl who developed galactorrhea after increasing his modifed-release oral MPH to 50 mg/day while under treatment of sertraline and very low dose haloperidol.